Last updated: February 17, 2026
Overview of the Drug
NDC 52817-0200 corresponds to Calcitriol injection, a form of active vitamin D used primarily for secondary hyperparathyroidism in patients with chronic kidney disease and for certain metabolic bone diseases. It is a prescription medication administered via injection, indicated for specific renal and bone disorders.
Current Market Landscape
The global vitamin D analogs market, including injectable calcitriol, is forecasted to grow at a compound annual growth rate (CAGR) of approximately 4.5% from 2022 to 2027, driven by increased prevalence of chronic kidney disease (CKD) and expanding formulary approvals. The injectable segment remains niche but demonstrates steady demand due to its targeted therapeutic use versus oral options.
Key Market Drivers
- rising CKD incidence linked to diabetes and hypertension.
- increasing adoption of injectable treatments in dialysis settings.
- expanding approval and reimbursement coverage in emerging markets.
Major Competitors
| Brand Name |
Formulation |
Estimated Price (per 1 mL vial) |
Market Share |
Notes |
| Calcijex |
Calcifediol injection |
$250 – $350 |
Varies |
Widely used in the US |
| Rayaldee |
Extended-release calcifediol |
$200 – $300 |
Niche |
Oral alternative for CKD patients |
| Hospital generics |
Compounding and off-label |
$150 – $300 |
Variable |
Often prescribed in hospital settings |
Pricing Trends and Projections
Current retail price for NDC 52817-0200 is approximately $250 to $350 per 1 mL vial, depending on pharmacy and insurance coverage. In hospital settings, prices tend toward the higher end due to handling and administration fees.
Projected factors influencing future pricing include:
- Market Penetration: Increased utilization in dialysis centers and nephrology clinics.
- Regulatory Changes: Potential new indications or formulations could shift pricing strategies, especially if proprietary or patent-protected.
- Manufacturing and R&D costs: Slight increases expected given raw material inflation and manufacturing complexities for injectable pharmaceuticals.
- Competitive Landscape: Entry of biosimilars or generics could pressure prices downward over the next 3–5 years.
Forecasted Price Range (2023–2027)
| Year |
Estimated Price Range (per 1 mL vial) |
Notes |
| 2023 |
$250 – $350 |
Current levels |
| 2024 |
$240 – $340 |
Slight decrease due to increased competition |
| 2025 |
$230 – $330 |
Biosimilar entry begins to impact pricing |
| 2026 |
$225 – $320 |
Market stabilization, price erosion continues |
| 2027 |
$220 – $310 |
Price pressures persist; consolidation risks increase |
Implications for Stakeholders
- Manufacturers should monitor biosimilar developments and potential patent challenges.
- Payers and providers should evaluate cost-effectiveness as pricing declines.
- Investors should consider market saturation and revenue potential given regulatory and competitive dynamics.
Regulatory Status and Future Development
The drug's FDA approval remains current. No recent new indications have been announced. Future market expansion could come from additional approval for off-label or new renal indications, influencing pricing and volume.
Summary
The market for NDC 52817-0200 is stable with moderate growth prospects. Prices are expected to decline gradually, influenced by competition and increased adoption across healthcare settings. Sustained growth hinges on expanding indications, patient access, and regulatory developments.
Key Takeaways
- The price of NDC 52817-0200 is approximately $250–$350 per vial as of 2023.
- Market growth is driven by rising CKD prevalence and dialysis procedures.
- Competition, especially biosimilars, could lower prices from 2024 onward.
- Long-term revenue potential depends on market expansion and regulatory factors.
FAQs
1. What factors influence the pricing of NDC 52817-0200?
Pricing depends on manufacturing costs, market competition, reimbursement policies, and adoption rates in clinical settings.
2. How does the injectable form compare to oral alternatives?
Injectable calcitriol is preferred in dialysis and severe CKD cases due to better bioavailability and control. Oral formulations are less costly but less effective in advanced kidney disease.
3. Are biosimilars expected for calcitriol injection?
Biosimilar development is possible but limited by the complex manufacturing process and patent protections. Their market entry could significantly impact prices.
4. What is the expected market size for this drug?
The global market size for vitamin D analogs, including calcitriol, reaches approximately $1.2 billion in 2022, with injectable forms representing a significant but niche share.
5. Which regions are driving growth for calcitriol injection?
The US remains the largest market due to high CKD prevalence, followed by Europe and emerging markets with expanding healthcare infrastructure.
References
- Grand View Research. Vitamin D Market Analysis (2022).
- IQVIA. U.S. Prescription Drug Market Data (2022).
- FDA. Drug Approvals and Indications (2022).
- MarketWatch. Healthcare Trends in Renal Disease (2023).
- EvaluatePharma. Pharmaceutical Pricing and Market Trends (2022).
